June 28, 2021
FDA: Class I recall of DeRoyal surgical procedure packs
Editor's Note
The Food and Drug Administration (FDA), on June 25, identified the recall of DeRoyal Industries’ surgical procedure packs as Class I, the most serious.
The recall was initiated because the packs contain 1% lidocaine that had been mislabeled as 0.5% bupivacaine.
The procedure packs are used for cardiac procedures, such as heart catheterizations, pacemaker-related procedures, and x-ray imaging (angiogram) procedures.
There have been no deaths, complaints, or reported injuries related to the issue.
Free Daily News
- CDC communication breakdown raises public health risk
- Study: Shorter radiation schedule matches safety of standard prostate cancer treatment
- Poll: Healthcare cybersecurity leaders overlook AI-enabled physical security gaps
- ASC improves hospital efficiency, maintains outcomes despite higher-acuity joint replacement patients
- Hospital support staff cuts raise risk of infection, delays in care
- Study: Blocking stress-linked prolactin surge relieves postoperative pain in women
- Report ranks states by nursing opportunity
- Report: Hospitals double down on ASCs as outpatient shift accelerates
- Centralized waitlists slash joint replacement wait times in Canada, study shows
- Airborne bacteria pose hidden threat in cardiac ORs, study warns
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement